Urology Doctors in Millburn, NJ Accepting Medicare

6 Urology doctors found. Showing 1 - 6

Dr. Mark Jonathan Mann, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 225 Millburn Ave Ste 304, Millburn, NJ 07041 Phone: 973-218-9400    Fax: 973-218-9420

Dr. Mubashir Shabil Billah, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 225 Millburn Ave, Millburn, NJ 07041 Phone: 973-218-9400    Fax: 973-218-9420

Merritt Harold Cohen, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 225 Millburn Ave, Suite 304, Millburn, NJ 07041 Phone: 973-218-9400    Fax: 973-218-9420

Eric K Seaman, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 225 Millburn Ave Ste 304, Millburn, NJ 07041 Phone: 973-218-9400    Fax: 973-218-9420

Stuart D. Shoengold, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 225 Millburn Ave, Suite 304, Millburn, NJ 07041 Phone: 973-218-9400    Fax: 973-218-9420

Alan S. Helfman, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 225 Millburn Ave, Blgd. C., Suite 304, Millburn, NJ 07041 Phone: 973-218-9400    Fax: 973-218-9420

News Archive

SIR to showcase latest minimally invasive treatments at 37th annual meeting

Health, science and medical reporters are invited to register now for the Society of Interventional Radiology's 37th Annual Scientific Meeting March 24 at Moscone Center (North), San Francisco, Calif. The meeting's theme, "IR Evidence," was chosen to focus on the results of care-changing investigations that showcase research into minimally invasive treatments that provide treatment options, advance patient care and improve quality of life.

Controlling the building blocks of life

A simple and reliable method for converting one of the simplest chemical entities into one of the most difficult-to-make molecular building blocks of life, with complete control over its shape, is reported by scientists at the University of Bristol in this week's Nature.

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

St. Jude Medical, Inc., a global medical device company, announced today at EuroPCR that the first patient was enrolled in the FAME II (Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease) trial.

Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers

Stand Up To Cancer and Mirati Therapeutics Inc. - a late-stage targeted oncology company - today announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst program.

Read more Medical News

› Verified 7 days ago